Skip to main navigation
Skip to search
Skip to main content
the UWA Profiles and Research Repository Home
Login
Home
Profiles
Organisations
Research output
Grants
Datasets
Prizes / Awards
Engagement / Activities
Press/Media
Units
Equipment
Impacts
Search by expertise, name or affiliation
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Graeme J Hankey
Research output
:
Contribution to journal
›
Review article
›
peer-review
10
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Health Care Cost
100%
Acetylsalicylic Acid
100%
Warfarin
100%
Apoplexy
100%
Clopidogrel
33%
Atrial Fibrillation
33%
Cost-Effectiveness Analysis
33%
Therapeutic Procedure
22%
Inpatient
22%
Antithrombotic
11%
Anticoagulation
11%
Dipyridamole
11%
Antithrombotic Therapy
11%
Dabigatran
11%
Dronedarone
11%
Nursing and Health Professions
Prevention
100%
Warfarin
100%
Alka-Seltzer
100%
Patient
66%
Cost Effectiveness Analysis
33%
Clopidogrel
33%
Atrial Fibrillation
33%
Anticoagulant Agent
22%
Combination Therapy
11%
Anticoagulation
11%
Dabigatran
11%
Dipyridamole
11%